- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Longer Follow-Up Confirms Superior Outcomes With Amivantamab Plus Chemo in EGFR-Mutant Advanced NSCLC
September 14th 2024, 3:47pm
Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.
Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC
September 14th 2024, 3:30pm
Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.
DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets
September 13th 2024, 7:20pm
T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
September 13th 2024, 5:37pm
The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
September 13th 2024, 5:00pm
BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
September 13th 2024, 4:59pm
Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.
Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma
September 13th 2024, 4:45pm
Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.
Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC
September 13th 2024, 4:35pm
Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.
Consolidation Durvalumab Shows Consistent Survival Benefit in LS-SCLC Regardless of Prior PCI and CRT Components
September 13th 2024, 3:48pm
Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.
Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status
September 13th 2024, 3:26pm
Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.
Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC
September 11th 2024, 5:06pm
IASLC World Conference on Lung Cancer
T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.
Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC
September 11th 2024, 5:04pm
IASLC World Conference on Lung Cancer
Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.
T-DXd Displays Clinical Benefit in HER2-Overexpressed Metastatic NSCLC
September 11th 2024, 4:55pm
IASLC World Conference on Lung Cancer
T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.
Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC
September 11th 2024, 4:12pm
IASLC World Conference on Lung Cancer
Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.
Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial
September 11th 2024, 1:20am
IASLC World Conference on Lung Cancer
Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure
September 10th 2024, 10:20pm
IASLC World Conference on Lung Cancer
Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.
Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC
September 10th 2024, 7:24pm
IASLC World Conference on Lung Cancer
Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.
Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC
September 10th 2024, 6:49pm
IASLC World Conference on Lung Cancer
Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.
Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC
September 10th 2024, 6:45pm
IASLC World Conference on Lung Cancer
The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.
Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC
September 10th 2024, 6:44pm
IASLC World Conference on Lung Cancer
Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.